Bernard Bihain

Biography

Bernard founded Genclis in 2004. After a Doctorate in Medicine from the Université Libre de Bruxelles, Bernard started an internship in surgery that he left to devote himself exclusively to research in the framework of a post- Columbia University, New York, USA. He was appointed Assistant Professor of Physiology at the University of Louisiana, New Orleans, USA. Bernard was awarded the Inserm Research Director's Competition and became Professor and President of the Department of Biochemistry at the University of Rennes, where he created the Inserm 391 unit, which he headed. He then headed the Genomics Department of Genset, a publicly traded genomics company and resold to Merck-Serono. He then became CSO de Valigen, leaving to devote himself to the creation of Genclis. He has actively contributed to the emergence of genomic technologies, his pragmatism as a surgeon is the driving force behind Genclis' translational activities. Bernard is the author of more than 50 publications in refereed journals. His works are cited in more than 5000 scientific articles.

Research Interest

Clinical science